window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : September 19, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Advanced Therapies

  • Advanced Therapies,Biotech & Pharma Business,Research & Development

    Oncodesign Services and Nexus BioQuest form preclinical research partnership

    Oncodesign Services and Nexus BioQuest have formed a preclinical research [...]

    September 17, 2026
  • Advanced Therapies,Biotech & Pharma Business,Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    NIH funds expanded access programme for Neurizon’s ALS therapy

    A US National Institutes of Health grant will fund an [...]

    September 16, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics

    Resolution Therapeutics partners with Blood Centers of America for RTX001 programme

    Resolution Therapeutics has partnered with Blood Centers of America to [...]

    September 16, 2026
  • Advanced Therapies,Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Resolution Therapeutics completes Phase 1/2 RTX001 liver disease trial dosing

    Resolution Therapeutics has treated the final patient in its Phase [...]

    September 16, 2026
  • Advanced Therapies,Biotech & Pharma Business,Pharmaceuticals and therapeutics,Research & Development

    Eleva separates biologics platform from Factor H therapy

    Eleva is separating its moss-based biologics platform from its clinical-stage [...]

    September 15, 2026
  • Advanced Therapies,Biotech & Pharma Business,Research & Development

    Circio raises NOK 200M (€18.6M) to advance in vivo CAR-T programme

    Circio has raised approximately NOK 200M (€18.6M) to advance its [...]

    September 15, 2026
  • Advanced Therapies,Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development

    Agenus reports deep responses with immunotherapy in Phase 2 colon cancer study

    Agenus has reported deep tumour responses and no observed colorectal [...]

    August 27, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Manufacturing & Supply Chain,Pharmaceuticals and therapeutics,Research & Development

    CEPI funds Minapharm’s Phase 1 Bundibugyo Ebola vaccine programme

    CEPI will provide up to $16.5 million to Minapharm to [...]

    August 27, 2026
  • Advanced Therapies,Drug Delivery & Formulation,Drug Discovery & Development,Research & Development

    Circio and Full Circles Therapeutics combine technologies for in vivo cell therapy

    Circio and Full Circles Therapeutics are combining circular RNA and [...]

    August 27, 2026
  • Advanced Therapies,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development

    Lumen Bioscience gets up to $7M to advance LMN-1001 into Phase 1

    Lumen Bioscience has received up to $7m in US government [...]

    August 25, 2026
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Sapience Therapeutics gets FDA clearance for ST316 FAP study
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • EURneffy recommended for emergency anaphylaxis treatment in NHS Wales
    Categories: Clinical & Regulatory, Drug Delivery & Formulation, Pharmaceuticals and therapeutics, Therapeutic Areas
  • Lifebit awarded three-year NIHR BioResource research environment contract
    Categories: Biotech & Pharma Business, Digital & Data, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top